Why did NYC Mayor Adams drop reelection bid?
How will Trump-led government shutdown impact economy?
Why is OPEC+ planning another oil output hike?
What caused recent surge in Nvidia stock value?
How are AI startups attracting massive funding rounds?
Why is Walmart keeping headcount flat amid AI changes?
What are the effects of Trump’s new tariff policies?
Sanofi Expands Insulin Savings Program To Cover All US Patients
benzinga.com/markets/large-cap/25/09/47896967/sanofi-expands-insulin-savings-program-to-cover-all-us-patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.
SNY is demonstrating bullish strength. Check out the latest…
This story appeared on benzinga.com, 2025-09-26 17:40:01.